Samsung Biologics Co.,Ltd. (KRX:207940)

Market Cap	77.82T +15.6%
Revenue (ttm)	4.56T +30.3%
Net Income	1.78T +64.7%
EPS	26,628.00 +74.9%
Shares Out	46.29M
PE Ratio	69.78
Forward PE	44.86
Dividend	n/a
Ex-Dividend Date	n/a

Volume	68,087
Average Volume	55,447
Open	1,639,000
Previous Close	1,681,000
Day's Range	1,501,000 - 1,650,000
52-Week Range	1,509,860 - 1,987,000
Beta	0.21
RSI	28.27
Earnings Date	Apr 29, 2026

About Samsung Biologics

Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates through Contract Development and Manufacturing Organization (CDMO), and Biopharmaceutical Development and Commercialization segments. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, fini...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 4,770
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 207940

Financial Performance

In 2025, Samsung Biologics's revenue was 4.56 trillion, an increase of 30.31% compared to the previous year's 3.50 trillion. Earnings were 1.78 trillion, an increase of 64.71%.